Natera, Inc. announced the company, along with its collaborators, will present new data on Natera's personalized, tumor-informed molecular residual disease test, Signatera, at the American Society of Clinical Oncology's 2022 Gastrointestinal Cancers Symposium, taking place January 20 – 22, 2022. Natera has two oral presentations and four collaborative poster presentations highlighting clinical findings on the performance of Signatera across colorectal (CRC), pancreatic and anal cancers. The oral presentations include an interim analysis from the GALAXY cohort of the CIRCULATE-Japan trial, based on 12-month outcomes from more than 1,000 patients, demonstrating how MRD testing can help predict treatment benefit for CRC patients post-surgery, regardless of stage.

A second oral presentation addresses results from the first major study on the utility of MRD testing for patients with pancreatic cancer, compared to the standard of care biomarker CA19-9.